Toggle Main Menu Toggle Search

Open Access padlockePrints

Expression of much gene products in laryngeal squamous cancer

Lookup NU author(s): Professor Vinidh Paleri, Professor Jeffrey Pearson, Dr David Bulmer, Emerita Professor Janet WilsonORCiD


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


OBJECTIVE. Mucins are high-molecular-weight glycoproteins present at the outer surface of mammalian cells. The objective of this study was to examine the expression of mucin (MUC) genes 3, 4, 5AC, 513, 6, and 7 in early and late laryngeal squamous cancer using the in situ hybridization technique. STUDY DESIGN: Retrospective analysis of pathological archive specimens. RESULTS: While MUC 3 and 7 are expressed in a small proportion of early cancers, MUC 5AC, 513, and 6 are not expressed in laryngeal squamous cancer. MUC 4 was expressed in 13 of the 30 patients. Ten patients and 3 patients with stage I and stage 4 disease respectively expressed MUC 4 gene (Fisher's exact, P = 0.02). MUC4-positive patients had a definite trend towards better survival (log rank test, P = 0.05). In the presence of tumor stage and comorbidity grade, Cox's proportional hazards model failed to statistically confirm the survival advantage provided by MUC 4 gene expression. CONCLUSION: There is a survival advantage for patients with advanced-stage nonmetastatic cancer when the MUC 4 gene is expressed. AIMS: To study the expression of mucin (MUC) genes 3, 4, 5AC, 513, 6, and 7 in early and advanced squamous cell cancer of the larynx; to attempt to correlate changes in gene expression with tumor stage by studying stage I and stage IV (AJCC, 1988) tumors.

Publication metadata

Author(s): Paleri V, Pearson JP, Bulmer D, Jeannon JP, Wight RG, Wilson JA

Publication type: Article

Publication status: Published

Journal: Otolaryngology - Head and Neck Surgery

Year: 2004

Volume: 131

Issue: 1

Pages: 84-88

ISSN (print): 0194-5998

ISSN (electronic): 1097-6817

Publisher: Mosby, Inc.